文献速递老年综合评估老年慢病共病管理

竞争性死亡风险对QRISK3心血管风险预测工具在老年及共病人群中预测性能的影响:外部验证人群队列研究

Effect of competing mortality risks on predictive performance of the QRISK3 cardiovascular risk prediction tool in older people and those with comorbidity: external validation population cohort study.
PubMed 文献 · Lancet Healthy Longev · 2021-01-01

该回顾性人群队列研究利用临床实践研究数据链数据,纳入无心血管病史或他汀治疗史的25-84岁患者,外部验证QRISK3并评估竞争性死亡风险对其预测性能的影响。

要点

  • 忽略竞争风险时,QRISK3对老年人明显高估心血管风险。
  • 考虑竞争风险后,QRISK3对老年及高共病人群系统性高估风险。

核心结论

  • QRISK3在全人群水平忽略竞争性死亡风险时表现良好,但在老年人和共病人群等关键亚组中表现明显较差,考虑竞争性死亡风险后表现更差。

研究设计与样本

  • 回顾性人群队列研究,使用临床实践研究数据链数据,纳入25-84岁无心血管病史或他汀治疗史、永久注册于全科 practice、至少1年达标数据并 linkage 至医院 Episode 统计出院和死亡数据的患者。

主要发现

  • 忽略竞争风险时,QRISK3在全人群和年轻人中校准优良,但对老年人显著高估。
  • 考虑竞争风险后,QRISK3系统性高估心血管风险,尤其在老年人和高共病人群中。

临床怎么用

  • 在老年及共病人群中应用QRISK3进行心血管风险预测时,需警惕其判别力下降和风险高估,尤其应考虑竞争性死亡风险的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary prevention of cardiovascular disease (CVD) is guided by risk-prediction tools, but these rarely account for the risk of dying from other conditions (ie, competing mortality risk). In England and Wales, the recommended risk-prediction tool is QRISK2, and a new version (QRISK3) has been derived and internally validated. We aimed to externally validate QRISK3 and to assess the effects of competing mortality risk on its predictive performance. METHODS: For this retrospective population cohort study, we used data from the Clinical Practice Research Datalink. We included patients aged 25-84 years with no previous history of CVD or statin treatment who were permanently registered with a primary care practice, had up-to-standard data for at least 1 year, and had linkage to Hospital Episode Statistics discharge and Office of National Statistics mortality data. We compared the QRISK3-predicted 10-year CVD risk with the observed 10-year risk in the whole population and in important subgroups of age and multimorbidity. QRISK3 discrimination and calibration were examined with and without accounting for competing risks. FINDINGS: Our study population included 1 484 597 women with 42 451 incident CVD events (4·9 cases per 1000 person-years of follow-up, 95% CI 4·89-4·99), and 1 420 176 men with 53 066 incident CVD events (6·7 cases per 1000 person-years, 6·66-6·78), with median follow-up of 5·0 years (IQR 1·9-9·2). Non-CVD death rose markedly with age (0·4% of women and 0·5% of men aged 25-44 years had a non-CVD death vs 20·1% of women and 19·6% of men aged 75-84 years). QRISK3 discrimination in the whole population was excellent (Harrell's C-statistic 0·865 in women and 0·834 in men) but was poor in older age groups (<0·65 in all subgroups aged 65 years or older). Ignoring competing risks, QRISK3 calibration in the whole population and in younger people was excellent, but there was significant over-prediction in older people. Accounting for competing risks, QRISK3 systematically over-predicted CVD risk, particularly in older people and in those with high multimorbidity. INTERPRETATION: QRISK3 performed well at the whole population level when ignoring competing mortality risk. The tool performed considerably less well in important subgroups, including older people and people with multimorbidity, and less well again after accounting for competing mortality risk. FUNDING: National Institute for Health Research.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Livingstone S, Morales DR, Donnan PT, et al. Effect of competing mortality risks on predictive performance of the QRISK3 cardiovascular risk prediction tool in older people and those with comorbidity: external validation population cohort study. Lancet Healthy Longev. 2021. PMID: 34100008. doi:10.1016/S2666-7568(21)00088-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。